Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.

Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.

Infliximab can trigger lupus-like symptoms in Crohn's disease patients.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Methotrexate plus prednisolone had the fewest serious side effects.

A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

RCS-01 therapy is safe and may improve skin structure by affecting gene expression.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Methotrexate is not proven effective for inducing remission in ulcerative colitis.

Ruxolitinib treatment may cause eyelash growth.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Topical Ruxolitinib may safely treat severe hair loss.

Stopping the medication infliximab and starting new treatments helped a woman's hair grow back and improved her scalp condition.

High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

CGRP MAbs treatment for migraines may also improve rosacea symptoms, but more research is needed to confirm its effectiveness and safety.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

Abatacept may help some people with alopecia areata regrow hair.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.

CAR-T therapy offers hope for children with hard-to-treat blood cancers.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Ritlecitinib is cost-effective for severe alopecia areata in Japan.